49,718 Shares in Palvella Therapeutics, Inc. $PVLA Purchased by Nicholas Investment Partners LP

Nicholas Investment Partners LP purchased a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 49,718 shares of the company’s stock, valued at approximately $7,598,000.

Several other large investors have also bought and sold shares of PVLA. Millennium Management LLC bought a new stake in Palvella Therapeutics during the first quarter worth $7,553,000. Goldman Sachs Group Inc. purchased a new stake in Palvella Therapeutics during the first quarter valued at about $533,000. Geode Capital Management LLC lifted its stake in shares of Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after buying an additional 79,787 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares during the period. Finally, Rhumbline Advisers purchased a new stake in shares of Palvella Therapeutics during the second quarter worth $224,000. 40.11% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at $327,860.34. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by insiders.

Palvella Therapeutics Price Performance

NASDAQ PVLA opened at $145.75 on Tuesday. Palvella Therapeutics, Inc. has a 1 year low of $49.13 and a 1 year high of $161.38. The stock has a market capitalization of $2.10 billion, a PE ratio of -30.18 and a beta of -0.17. The company’s 50 day simple moving average is $142.93 and its two-hundred day simple moving average is $125.24.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, research analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating and set a $270.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $209.14.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.